Program
Candidate UTI vaccine HTD formulation 2
Its studies are mostly in Urinary Tract Infections, led by GlaxoSmithKline.
Furthest: phase 2, since Nov 20, 20241 company-led study, 1 open or runningNext primary completion: May 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 2since Nov 20, 2024 | Nov 20, 2024 | May 31, 2027phase 2 · NCT06702449 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2024First study: phase 2 study in Urinary Tract InfectionsFirst studyNCT06702449 · 448 planned · United States, South Africa
Ahead
- May 31, 2027Primary completion: phase 2 study in Urinary Tract InfectionsNCT06702449
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Candidate UTI vaccine HTD formulation 2”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06702449Urinary Tract Infections · United States, South Africa | 2 | Recruiting | May 31, 2027 | 448 |
How it is read
Names in the registry
- “Candidate UTI vaccine HTD formulation 2”, 1 entry
Conditions, from the studies’ own filings
- Urinary Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.